-
公开(公告)号：US20220414878A1
公开(公告)日：2022-12-29
申请号：US17895221
申请日：2022-08-25
Inventor： David Frazier Jarrard , Bing Yang , Peter LaViolette
Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial thickness or gland lumen roundness of the tissue, wherein an increase in epithelial thickness or a decrease in gland lumen roundness indicates the presence of prostate cancer or a prostate cancer field defect.
-
公开(公告)号：US20220307091A1
公开(公告)日：2022-09-29
申请号：US17837731
申请日：2022-06-10
Applicant: Wisconsin Alumni Research Foundation
Inventor： David Frazier Jarrard , Bing Yang
IPC: C12Q1/6886
Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
-
公开(公告)号：US11449987B2
公开(公告)日：2022-09-20
申请号：US16723595
申请日：2019-12-20
Inventor： David Frazier Jarrard , Bing Yang , Peter LaViolette
Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial thickness or gland lumen roundness of the tissue, wherein an increase in epithelial thickness or a decrease in gland lumen roundness indicates the presence of prostate cancer or a prostate cancer field defect.
-
公开(公告)号：US20180135136A1
公开(公告)日：2018-05-17
申请号：US15811876
申请日：2017-11-14
Applicant: Wisconsin Alumni Research Foundation
Inventor： David Frazier Jarrard , Bing Yang
IPC: C12Q1/6886 , C12Q1/6853 , C12Q1/6806 , C12Q1/686
CPC classification number: C12Q1/6886 , C12Q1/6806 , C12Q1/6853 , C12Q1/686 , C12Q2337/00 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/154 , C12Q2600/158
Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of PLA2G16, CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
-
5.发明申请UNBIASED DNA METHYLATION MARKERS DEFINE AN EXTENSIVE FIELD DEFECT IN HISTOLOGICALLY NORMAL PROSTATE TISSUES ASSOCIATED WITH PROSTATE CANCER: NEW BIOMARKERS FOR MEN WITH PROSTATE CANCER 审中-公开未经预期的DNA甲基化标记定义了与前列腺癌相关的组织学正常前列腺组织中的广泛的现场缺陷：具有前列腺癌的男性新生物标志物公开(公告)号：US20140296355A1
公开(公告)日：2014-10-02
申请号：US14226291
申请日：2014-03-26
Applicant: Wisconsin Alumni Research Foundation
Inventor： David Frazier Jarrard , Bing Yang
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/154
Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
Abstract translation: 一种检测人受试者中前列腺癌斑块缺陷的存在的方法，包括以下步骤：（a）从人受试者获得基因组DNA，和（b）定量至少一个靶区域中的甲基化，所述靶区域选自CAV1， EVX1，MCF2L，FGF1，NCR2和WNT2以及EXT1和SPAG4靶标，其中显着的甲基化变化表明前列腺癌或前列腺癌场缺陷的存在，其中该变化相对于不具有前列腺癌的第二人类受试者的组织 。
-
Patent Agency Ranking
公开(公告)号：US20210404018A1
公开(公告)日：2021-12-30
申请号：US17474174
申请日：2021-09-14
Applicant: Wisconsin Alumni Research Foundation
Inventor： David Frazier Jarrard , Bing Yang
IPC: C12Q1/6886 , C12Q1/6853 , C12Q1/6806 , C12Q1/686
Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject. The method includes (a) obtaining genomic DNA from the human subject and (b) determining methylation status in at least one target region selected from the group consisting of PLA2G16, CAV1, EVX1, MCF2L, FGF1, NCR2, WNT2, EXT1, and SPAG4, wherein methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
-
公开(公告)号：US20180334723A1
公开(公告)日：2018-11-22
申请号：US15970235
申请日：2018-05-03
Applicant: Wisconsin Alumni Research Foundation
Inventor： David Frazier Jarrard , Bing Yang
IPC: C12Q1/6886
CPC classification number: C12Q1/6886 , C12Q2600/154
Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
-
公开(公告)号：US10131953B2
公开(公告)日：2018-11-20
申请号：US14226291
申请日：2014-03-26
Applicant: Wisconsin Alumni Research Foundation
Inventor： David Frazier Jarrard , Bing Yang
IPC: C40B30/04 , C12Q1/68 , C12Q1/6886
Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
-
9.发明申请公开(公告)号：US20180136215A1
公开(公告)日：2018-05-17
申请号：US15812015
申请日：2017-11-14
Applicant: Wisconsin Alumni Research Foundation
Inventor： David Frazier Jarrard , Bing Yang
IPC: G01N33/574
CPC classification number: G01N33/57434 , G01N2800/7028 , G06K9/00147 , G06K2209/05 , G06T7/0012 , G06T2207/30024 , G06T2207/30081
Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial percentage of the tissue, wherein an epithelial percentage greater than 39% indicates the presence of prostate cancer or a prostate cancer field defect.
-
公开(公告)号：US12071672B2
公开(公告)日：2024-08-27
申请号：US17474174
申请日：2021-09-14
Applicant: Wisconsin Alumni Research Foundation
Inventor： David Frazier Jarrard , Bing Yang
IPC: C12Q1/68 , C12Q1/6806 , C12Q1/6853 , C12Q1/686 , C12Q1/6886
CPC classification number: C12Q1/6886 , C12Q1/6806 , C12Q1/6853 , C12Q1/686 , C12Q2337/00 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/154 , C12Q2600/158
Abstract: A method of detecting the presence of a prostate cancer field defect in a human subject. The method includes (a) obtaining genomic DNA from the human subject and (b) determining methylation status in at least one target region selected from the group consisting of PLA2G16, CAV1, EVX1, MCF2L, FGF1, NCR2, WNT2, EXT1, and SPAG4, wherein methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.032 seconds)
